Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Product Upgrade

9th Nov 2011 07:00

RNS Number : 6885R
Cyprotex PLC
09 November 2011
 



9 November 2011

 

Cyprotex PLC

 

Cyprotex Improves Predictive Technology for Pharmacokinetics

 

Major Upgrade to Cloe® PK Pharmacokinetic Model

 

Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today announces major enhancements to Cloe® PK, Cyprotex's pharmacokinetic prediction software.

 

Cloe® PK™ enables scientists in the drug discovery and agrochemical industries to use ADME and physicochemical data to predict human and rodent pharmacokinetics (process by which a drug is absorbed, distributed, metabolised, and eliminated by the body). These predictions allow prospective compounds to be ranked and prioritised for success potential prior to or even without the need for expensive and time-consuming in vivo studies. Cloe® PK has already been shown to predict aspects of human pharmacokinetics better than extrapolation from animal in vivo studies.

 

Twenty-seven key parameters are used to measure Cloe® PK's performance. The enhancements to Cloe® PK have improved accuracy on 16 of these 27 parameters. These parameters summarise the model's capability to predict aspects of human and rodent pharmacokinetics, including clearance, distribution, half-life, and oral absorption.

 

Several of the enhancements were facilitated through collaboration with one of Cyprotex's major clients who provided Cyprotex with a large in vivo dataset for building and testing the improvements to the model.

 

Cloe® PK is available either as a site license, or on an as-needed basis via Cyprotex's online portal, Cloe® Gateway (www.cloegateway.com).

 

Cyprotex's Chief Scientific Officer, Dr Katya Tsaioun, comments: "Cyprotex is the only ADME Tox contract research organisation with in-house expertise in both in vitro and in silico ADME and has a unique capacity to help clients understand the relationship between in vitro data, in silico predictions, and in vivo performance*. Cyprotex continues to refine the Cloe® PK software and this latest enhancement increases the model's reliability and usability. Cloe® PK speeds up the process of selecting compound candidates to create a drug and it reduces the need for expensive and time-consuming animal pharmacokinetic studies."

 

* in vitro - in tube; in silico - computer generated; and in vivo - in animal

 

For more information, see http://www.cyprotex.com/cloepredict/physiological_modelling/cloe-pk/ .

 

For further information:

 

Cyprotex PLC

Tel: +44 (0) 1625 505 100

Dr Anthony Baxter, Chief Executive Officer

John Dootson, Chief Financial Officer

Mark Warburton, Chief Operating Officer and Legal Counsel

ir@cyprotex.com

www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)

Tel: +44 (0) 203 205 7500

Shaun Dobson

Claes Spang

 

shaun.dobson@singercm.com

claes.spang@singercm.com

www.singercm.com

FTI Consulting

Tel: +44 (0) 20 7831 3113

Ben Brewerton

Ben Atwell

Mo Noonan

cyprotex@fticonsulting.com

www.fticonsulting.com

 

 

 

Notes to Editors:

 

Cyprotex PLC

 

Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PRLZMMGMMRNGMZM

Related Shares:

CRX.L
FTSE 100 Latest
Value8,766.98
Change50.53